BEAM
Beam Therapeutics Inc
24.50$
+0.5%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
Beam Therapeutics Inc (BEAM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -66 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4.0 | -4.0 | -9.4 | -3.0 | -26 | -11 | -17 | -18 | -27 | -23 | -21 | -24 | -39 | -33 | 3.0 | 1.8 | 218 | -52 | -74 | -69 | -110 | -85 | -90 | 135 | -100 | -83 | -88 | -76 | -104 | -76 | -81 | -83 | -129 | -66 | -359 | |
| 0.0 | 0.0 | 0.1 | 0.5 | 0.7 | 0.9 | 0.9 | 1.0 | 1.1 | 1.1 | 1.2 | 1.3 | 1.4 | 1.7 | 1.8 | 2.6 | 3.3 | 3.4 | 3.5 | 3.9 | 4.6 | 4.8 | 5.2 | 5.4 | 5.4 | 5.6 | 5.5 | 15 | 5.5 | 5.5 | 5.6 | 5.7 | 5.6 | 5.4 | 22 | |
| 0.6 | 0.6 | 4.3 | 1.5 | 0.9 | 2.1 | 2.0 | 2.1 | 2.8 | 2.8 | 3.0 | 6.8 | 4.6 | 10 | 13 | 16 | 18 | 22 | 22 | 22 | 24 | 26 | 26 | 23 | 29 | 32 | 30 | 30 | 27 | 24 | 23 | -74 | 19 | 19 | -13 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 163 | 30 | -26 | 19 | 13 | 22 | 48 | -53 | 18 | 27 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.3 | 0.3 | -1.0 | 8.4 | -15 | 2.5 | -2.6 | 4.6 | -4.6 | -1.8 | 5.6 | 6.2 | -1.6 | 12 | 56 | 45 | 271 | 1.2 | -10 | -10 | -45 | -20 | -20 | -32 | -38 | -26 | -26 | -21 | -25 | 3.4 | -7.1 | -102 | -56 | 26 | -139 | |
| 0.6 | 0.6 | 0.7 | 11 | 2.4 | 6.6 | 1.4 | 2.2 | 3.0 | 2.4 | 2.8 | 8.1 | 11 | 16 | 5.8 | 13 | 7.3 | 22 | 12 | 8.3 | 6.0 | 16 | 7.9 | 3.6 | 2.4 | 2.0 | 1.6 | 3.0 | 3.1 | 3.1 | 5.0 | 3.7 | 2.2 | 2.4 | 13 | |
| -0.6 | -0.6 | -1.0 | -11 | -2.4 | -95 | 14 | 17 | -77 | 23 | 35 | -81 | -280 | -13 | 76 | -77 | -537 | -1.3 | -36 | 113 | 25 | -41 | -10 | 98 | -53 | 87 | 25 | 126 | -125 | -170 | 66 | 108 | 25 | -9.9 | 189 | |
| – | – | – | – | – | – | – | 13 | 1.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | -23 | 3.1 | – | – | – | – | – | – | – | 56 | 23 | 2.1 | – | 99 | 108 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | -0.5 | -0.5 | -0.5 | -0.5 | -0.6 | -0.6 | -0.6 | -0.6 | -0.6 | -0.6 | – | – | – | – | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 94 | 0.0 | 94 | |
| 25 | 25 | 9.9 | 120 | 38 | 0.0 | 2.7 | 0.7 | 193 | -0.8 | 0.1 | 130 | 253 | 160 | 321 | 22 | 56 | 22 | 1.6 | 32 | 98 | 108 | 37 | 34 | 2.9 | 0.1 | 1.3 | 3.4 | 473 | 1.1 | 1.7 | 1.9 | 97 | 7.5 | 108 | |
| 20 | 20 | -0.5 | 106 | 9.7 | -106 | -0.1 | -0.5 | 89 | -0.7 | 14 | 24 | -65 | 115 | 400 | -54 | -263 | -31 | -109 | 76 | 14 | -19 | -63 | 267 | -150 | 4.6 | -62 | 53 | 244 | -246 | -14 | 27 | -6.7 | -68 | -62 | |
| -4.6 | -4.6 | -10 | -14 | -28 | -18 | -18 | -20 | -30 | -25 | -24 | -32 | -50 | -49 | -2.8 | -12 | 211 | -74 | -86 | -77 | -116 | -101 | -98 | 131 | -102 | -85 | -90 | -79 | -107 | -80 | -86 | -87 | -131 | -69 | -373 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.